Improved production, and evaluation of Cu-67 for tumor radioimmunotherapy
- Brookhaven National Lab., Upton, NY (United States); and others
Copper-67 is a radionuclide of great interest for radioimmunotherapy. We report labeling and biodistribution results with the anti-CEA F(ab`){sub 2} monoclonal antibody (MAb). The anti-CEA F(ab`){sub 2} MAb was conjugated with 1,4,7,10-tetraazacyclodo-decane-and 1,4,8,11-tetraazacyclotetradecane-N,N`,N``,N```-tetraacetic acid (DOTA and TETA) using their mono NHS esters. The ligands were synthesized using a simple large scale method and the MAb conjugates were labeled with Cu-67 (90{plus_minus}5% yield, 98% in-vitro serum stability at 4d, and immunoreactivity 80{plus_minus}10%). Data in tumor (LS-174 T cells) xenografted nude mice showed similar tumor uptake (% ID/g) for both DOTA and TETA at 24h (32.4 vs 35.7) and 96h (14.6 vs 17.1). The DOTA conjugate showed slightly higher liver uptake (24h: 14.7 vs 10.4; 96h: 7.05 vs 5.3) and blood uptake (24h: 6.16 vs 4.73; 96h: 0.72 vs 0.46) while the TETA conjugate showed higher kidney uptake (24h: 12.8 vs 4.8; 96h: 8.6 vs 4.1). These results are quite favorable and warrant further study of these Cu-67-MAb conjugates for radioimmunotherapy.
- Research Organization:
- Brookhaven National Laboratory (BNL), Upton, NY
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 198108
- Report Number(s):
- CONF-940605--
- Journal Information:
- Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: Suppl.5 Vol. 35; ISSN 0161-5505; ISSN JNMEAQ
- Country of Publication:
- United States
- Language:
- English
Similar Records
A comparative study of Co-57 labeled 4-ICE and 4-BACE immunoconjugates: Effect of conjugation method and antibody/tumor model system on biodistribution
Radioimmunotherapy: Development of an effective approach